Advertisement
Chugai Pharmaceutical (TSE:4519) Second Quarter 2025 Results
Key Financial Results
- Revenue: JP¥290.0b (down 8.2% from 2Q 2024).
- Net income: JP¥97.2b (down 13% from 2Q 2024).
- Profit margin: 34% (down from 35% in 2Q 2024). The decrease in margin was driven by lower revenue.
- EPS: JP¥59.04 (down from JP¥67.98 in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Chugai Pharmaceutical Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 7.9%.
Looking ahead, revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Japan.
Performance of the Japanese Pharmaceuticals industry.
The company's shares are up 4.8% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 1 warning sign for Chugai Pharmaceutical you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4519
Chugai Pharmaceutical
Engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
Outstanding track record with flawless balance sheet and pays a dividend.
Similar Companies
Market Insights
Advertisement
Weekly Picks
ST
stuart_roberts on Unicycive Therapeutics ·
Looking to be second time lucky with a game-changing new product
Fair Value:US$21.5363.1% undervalued
130 followersusers have followed this narrative
0 commentsusers have commented on this narrative
18 likesusers have liked this narrative
DE
Degen_GCR on Everpure ·
Second order memory play likely to double in a year
Fair Value:US$18051.5% undervalued
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
DO
Double_Bubbler on Intuitive Machines ·
Intuitive Machines: To The Moon and Beyond!
Fair Value:US$42.323.4% undervalued
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
YI
yiannisz on AppLovin ·
AppLovin’s AI Engine Is Printing Profit
Fair Value:US$989.2451.6% undervalued
21 followersusers have followed this narrative
1 commentusers have commented on this narrative
1 likeusers have liked this narrative
Recently Updated Narratives
KA
kapirey on Pilatus Marine ·
Thailand-based provider of LPG (liquefied petroleum gas) and petrochemical transportation services
Fair Value:฿0.6314.3% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
KA
kapirey on Cirrus Aircraft ·
Cirrus Aircraft leadership in personal aviation.
Fair Value:HK$55.1434.6% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
KA
kapirey on Sinopharm Group ·
value + defensive emerging markets healthcare
Fair Value:HK$18.862.1% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
GO
GoldenSands on QuantumScape ·
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality
Fair Value:US$8590.6% undervalued
108 followersusers have followed this narrative
2 commentsusers have commented on this narrative
31 likesusers have liked this narrative
KI
Kingman1152 on NVIDIA ·
NVIDIA will see a profit margin surge of 55% in the next 5 years
Fair Value:US$305.228.1% undervalued
70 followersusers have followed this narrative
2 commentsusers have commented on this narrative
24 likesusers have liked this narrative
AN
AnalystConsensusTarget on Microsoft ·
Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks
Fair Value:US$561.9326.6% undervalued
1399 followersusers have followed this narrative
2 commentsusers have commented on this narrative
12 likesusers have liked this narrative
